Correction: Chronic Noncancer Pain Management and Opioid Overdose

2010 ◽  
Vol 152 (6) ◽  
pp. 408
2020 ◽  
Vol 23 (1) ◽  
pp. 123-134
Author(s):  
Launette M. Rieb ◽  
Zainab Samaan ◽  
Andrea D. Furlan ◽  
Kiran Rabheru ◽  
Sid Feldman ◽  
...  

BackgroundIn Canada, rates of hospital admission from opioid overdose are higher for older adults (≥ 65) than younger adults, and opioid use disorder (OUD) is a growing concern. In response, Health Canada commissioned the Canadian Coalition of Seniors’ Mental Health to create guidelines for the prevention, screening, assessment, and treatment of OUD in older adults.MethodsA systematic review of English language literature from 2008–2018 regarding OUD in adults was conducted. Previously published guidelines were evaluated using AGREE II, and key guidelines updated using ADAPTE method, by drawing on current literature. Recommendations were created and assessed using the GRADE method.ResultsThirty-two recommendations were created. Prevention recommendations: it is key to prioritize non-pharmacological and non-opioid strategies to treat acute and chronic noncancer pain. Assessment recommendations: a comprehensive assessment is important to help discern contributions of other medical conditions. Treatment recommendations: buprenorphine is first line for both withdrawal management and maintenance therapy, while methadone, slow-release oral morphine, or naltrexone can be used as alternatives under certain circumstances; non-pharmacological treatments should be offered as an integrated part of care.ConclusionThese guidelines provide practical and timely clinical recommendations on the prevention, assessment, and treatment of OUD in older adults within the Canadian context.


2019 ◽  
Vol 32 (4) ◽  
pp. 559-566
Author(s):  
Natalia P. Arizmendez ◽  
Fabiana Kotovicz ◽  
Jessica J. F. Kram ◽  
Dennis J. Baumgardner

2009 ◽  
Vol 49 (5) ◽  
pp. e102-e109
Author(s):  
Emily Weidman-Evans ◽  
Tibb F. Jacobs ◽  
Philip Isherwood ◽  
Jeffery D. Evans ◽  
Tara Jenkins

2017 ◽  
Vol 32 (5) ◽  
pp. 558-567 ◽  
Author(s):  
Brandi L. Bowers ◽  
Andrew J. Crannage

Nationally, the prescription of opioids for acute and chronic pain is increasing. As opioid use continues to expand and become of increased concern for health-care practitioners, so do the adverse effects and long-term management of those effects. Opioid-induced constipation (OIC) presents a unique challenge because tolerance does not develop to this particular adverse effect, making chronic pain management a delicate balance between relieving pain and preventing long-term adverse effects such as constipation and dependence. Several agents have been developed for the treatment of OIC in patients with chronic noncancer pain on the basis of short-term studies of 12 weeks or less. However, chronic pain management often extends beyond this 12-week boundary, resulting in health-care professionals questioning the safety and efficacy of continued treatment with OIC agents. This review evaluates available literature on long-term treatment of OIC in patients with chronic noncancer pain with lubiprostone, naloxegol, and methylnaltrexone as well as preliminary results of the recently completed naldemedine long-term trial, COMPOSE-3.


Pain Medicine ◽  
2017 ◽  
Vol 19 (3) ◽  
pp. 533-540 ◽  
Author(s):  
Suzanne Nielsen ◽  
Amy Peacock ◽  
Nicholas Lintzeris ◽  
Raimondo Bruno ◽  
Briony Larance ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document